Consistency of Response With Rimegepant in Acute Treatment of Migraine

Study Summary

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

Conditions

Migraine

Interventions / Drugs

Rimegepant for acute migraine treatment

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment250 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.191067+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.